Outcomes of single-centre experience of hepatic resection and cryoablation of sarcoma liver metastases.
BACKGROUND
Liver metastasis from sarcoma in metastatic disease is common and its effect on prognosis remains ill defined. Surgery remains paramount in sarcoma management; however, there is inadequate literature reporting the role of hepatic surgery as treatment for sarcoma liver metastases.


METHODS
Fifteen patients who underwent hepatic resection for metastatic sarcoma between January 1, 1995 and January 1, 2009 were identified from a prospective hepatobiliary database. Clinicopathologic, operative, recurrence, and long-term survival data are presented.


RESULTS
Three patients had synchronous liver metastases. The median time to developing liver metastasis was 26 (range, 0-206) months. The overall median survival from hepatic resection of liver metastasis was 103 (95% confidence interval, 6-200) months with a 5- and 10-year survival of 51% and 37%, respectively. The median disease-free survival from hepatic resection was 14 (95% confidence interval, 11-18) months. CD117 positive tumors was associated with an improved survival with a 3-year survival of 80% compared with 33% in CD117 negative tumors (P = 0.02).


CONCLUSIONS
Hepatic resection for sarcoma liver metastases with or without extrahepatic disease is a reasonable management strategy if a complete resection may be achieved. Concomitant treatment of CD117 positive tumors with imatinib leads to long-term survival.
Chua
Terence C
TC
Department of Surgery, University of New South Wales, St. George Hospital, New South Wales, Sydney, Australia.
Chu
Francis
F
Morris
David L
DL
D000328:Adult; D000368:Aged; D003452:Cryosurgery; D005260:Female; D006498:Hepatectomy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012509:Sarcoma / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D016896:Treatment Outcome